Evidence map›Paper›PMID 37773417›Full record

Observational studyJournal of neurology2024

Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.

Pablo Rodríguez de Vera Gómez, Mariola Méndez Muros, Alberto Torres Cuadro, Francisco Javier Toyos Sáenz de Miera, Rocío López Ruiz, Raquel Guerrero Vázquez, Juan Jesús García González, Antonio Manuel Garrido Hermosilla, Tomás Martín Hernández

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Medication-associated thyroid eye disease: a review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pablo Rodríguez de Vera GómezEndocrinology and Nutrition Department, University Hospital Virgen de la Macarena, Avenida Dr Fedriani 3, 41009, Seville, Spain. pablordevera@gmail.com.ORCID http://orcid.org/0000-0002-0951-5428
Mariola Méndez MurosEndocrinology and Nutrition Department, University Hospital Virgen de la Macarena, Avenida Dr Fedriani 3, 41009, Seville, Spain. mariolamendezmuros@hotmail.com.
Alberto Torres CuadroEndocrinology and Nutrition Department, University Hospital Virgen de la Macarena, Avenida Dr Fedriani 3, 41009, Seville, Spain.
Francisco Javier Toyos Sáenz de MieraRheumatology Department, University Hospital Virgen de la Macarena, Seville, Spain.
Rocío López RuizNeurology Department, University Hospital Virgen de la Macarena, Seville, Spain.
Raquel Guerrero VázquezEndocrinology and Nutrition Department, University Hospital Virgen de la Macarena, Avenida Dr Fedriani 3, 41009, Seville, Spain.
Juan Jesús García GonzálezEndocrinology and Nutrition Department, University Hospital Juan Ramón Jiménez, Huelva, Spain.
Antonio Manuel Garrido Hermosilla *Ophthalmology Department, University Hospital Virgen de la Macarena, Seville, Spain.
Tomás Martín Hernández *Endocrinology and Nutrition Department, University Hospital Virgen de la Macarena, Avenida Dr Fedriani 3, 41009, Seville, Spain.
Hospital Universitario Virgen Macarena · ESAndalusian Health Service · ESHospital Juan Ramón Jiménez · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextTreatment with Alemtuzumab (ALZ) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) is associated with the development of ALZ-induced Graves' disease (GD-ALZ). Some cases may develop associated Graves´ Orbitopathy (GO-ALZ), with possible visual compromise.

aimThe aim of this study was to describe the main clinical and biochemical characteristics of GD-ALZ, as well as the clinical course of a case series of GO-ALZ

methodsThis study is a retrospective observational study, carried out in a reference hospital for the care of patients with RRMS in Spain. Cases treated with ALZ in the period 2014-2022 were included. GO-ALZ cases were identified among those with clinical symptoms compatible with thyroid eye disease after initiating ALZ treatment.

resultsA total of 135 cases, with a mean follow-up of 69.6 months after the first ALZ cycle, were included. The incidence of GD-ALZ was 32.6% (44/135), with a predominance of women (77.3%) and mean age of 41.9 years. The presence of first-degree relatives with hypothyroidism was identified as risk factor for the development of GD-ALZ (adjusted P-value: 0.02). GO-ALZ was diagnosed in 6 cases (incidence: 13.6%), of which 3 had severe clinical forms of GO, requiring anti-IL-6 treatment. A favorable response was reported in all of them, with a significant decrease in disease activity and improvement in proptosis.

conclusionsWe report one of the largest cohorts of GD-ALZ and GO-ALZ cases. The diagnosis of these entities should be taken into account in patients treated with Alemtuzumab, given the risk of developing severe clinical forms. In moderate-severe forms of GO-ALZ, drugs with anti-IL-6 activity are a safe and effective option.

Indexed as

Graves DiseaseGraves OphthalmopathyMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingAdultAlemtuzumabFemaleHumansMaleAlemtuzumabAlemtuzumabGraves’ orbitopathyHyperthyroidismRelapsing–remitting multiple sclerosisTocilizumab

Identifiers

PMID37773417
OpenAlexW4387186749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.